Rasa has launched two coffee alternative mixes with adaptogenic herbs and mushrooms instead of caffeine, the Classic Rasa and Café Rasa.
Rasa CEO and founder, Lopa van der Mersch, said Classic Rasa, which is made of roasted chicory, burdock root, and date seed to create a dark, rich, and sweet blend, is the most coffee-like alternative out there.
It also has adaptogens: red Asian ginseng, cordyceps, rhodiola, gynostemma, shatavari, and maca.
Meanwhile, Café Rasa blends freeze-fried coffee from Chiapas, Mexico, with adaptogens that are said to soften coffee’s downsides whilst supplementing caffeine’s fatigue-fighting abilities.
According to van der Mersch, the two new mixes open new channels of distribution and provide everyone with the opportunity to drink Rasa.
Co-founder, Ben LeVine, added that their process includes brewing the herbs over several hours like a standard decoction, then drying it and granulating it to produce a supremely delicious, dissolvable, and bioavailable mix.


Stuck in a creativity slump at work? Here are some surprising ways to get your spark back
BOJ Set to Raise Rates to 1.25% as Inflation Risks Build
Gold Prices Steady Ahead of U.S. Inflation Data and Fed Decision
Debate over H-1B visas shines spotlight on US tech worker shortages
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds
Why financial hardship is more likely if you’re disabled or sick
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
Why have so few atrocities ever been recognised as genocide?
Central Banks Could Buy 20,000 Tonnes of Gold: BofA
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility?
The pandemic is still disrupting young people’s careers
China Buys 1 Million Tons of U.S. Soybeans Ahead of Xi Visit
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain
Longsys Raises $903 Million in Hong Kong IPO as Shares Debut Flat
Trump Threatens Bombardier U.S. Sales Ban
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 



